Division of Medical Oncology

Head of Division: Prof Soon Thye LIM

Department of Breast Oncology

Senior Consultant

Dr Rebecca DENT
Dr Yoon Sim YAP
Dr Raymond NG
Dr Elaine Hsuen LIM
Consultant Dr Guek Eng LEE
Dr Kiley LOH
Associate Consultant Dr Tira TAN
Dr Sok Yuen BEH


Department of Gynae Oncology

Senior Consultant

Dr John CHIA
Dr Lay Tin SOH
Consultants Dr Wen Yee CHAY

Department of Lymphoma Oncology

Senior Consultant

Prof LIM Soon Thye
Dr Miriam TAO
Adj A/Prof Richard QUEK 
Consultant Dr Mohd Farid
Dr Tiffany TANG

Department of Sarcoma Oncology

Senior Consultant

Adj A/Prof Richard QUEK 

Consultant Dr Mohd Farid

Department of Gastrointestinal Oncology

Senior Consultant

Dr CHOO Su Pin
A/Prof Han Chong TOH
A/Prof Wen Hsin KOO
A/Prof Simon ONG
Dr Chee Kian THAM
Dr Joanne NGEOW
Dr Matthew NG
Dr Iain TAN
Dr David TAI
Dr Clarinda CHUA
Dr Si-Lin KOO

Department of Thoracic and Head & Neck Oncology

Senior Consultant

A/Prof Eng Huat TAN
A/Prof Darren LIM
Dr Mei Kim ANG
Dr Chee Keong TOH 
Dr Quan Sing NG
Dr Daniel TAN
Dr Amit Jain
Associate Consultant  Dr Wan Ling TAN

Department of Urologic Oncology

Senior Consultant

Dr Chee Keong TOH
Dr Quan Sing NG

Consultant Dr Ravindran KANESVARAN
Visiting Consultant Dr Min-Han TAN


Principle Investigator

Dr Boon Tin CHUA


Principle Investigator
Principle Investigator Dr Choon Kiat ONG  DMO-Research NCCS
*Click on each tumour type to view the list of clinical trials open to recruitment.  

Research Programs

Singapore Lymphoma Study (SLS)

Lymphoid neoplasms are the 5th most common cancer in males and 6th most common in females in Singapore. A rising incidence was noted which led to the beginning of the Singapore Lymphoma Study in January 2005.

Currently, epidemiology and clinical data on lymphoid neoplasms is derived mainly from Western series. An increasing body of information from our centre and collaborations with other healthcare institutions suggest that geographic localities as well as ethnicity are important factors and extrapolation of experience and data from the West to the Asian setting may have limitations. More importantly, the detailed clinical and molecular data obtained from this study will form the basis of all future research and healthcare planning.

The main purpose of study is to exhaustively evaluate the molecular characteristics of lymphoma, particular subtypes that occur at higher frequencies in Asians and subsequently to develop new biomarkers, diagnostic assays, treatment targets and novel treatment strategies, particularly against lymphoma subtypes unique to Asians.

The SLS, headed by Prof Lim Soon Thye (Head of Division of Medical Oncology and Principal Investigator of Translational and Clinical Research Programme in Lymphoma), aims to examine the clinical and pathological profile of lymphoid malignancies (non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, chronic lymphocytic leukaemia) in Singapore with respect to mode of presentation, clinical features, histologic and immunophenotypic distribution. We hope to evaluate the risk profile of lymphoid malignancies associated with lifestyle factors (e.g. fruit/vegetables, meat intake, alcohol consumption and use of hair dyes), exposure to specific infectious agents and occupational exposure to pesticides and benzene. The SLS forms a major component of the National Lymphoma Translational and Clinical Research (TCR) Program, which is supported by the National Medical Research Council (NMRC).

* Click here for more information on Lymphoma Genomics Translational Laboratory
Lung Cancer Consortium Singapore (LCCS)

The Lung Cancer Consortium Singapore began in 2001 to provide a tissue and clinical data bank to support lung cancer research. To date, there are 1978 patients enrolled and daily screenings of potential patients conducted. Daily recruitment of screened patients and collection of tissue samples are carried as well.

The need to start up the LCCS was due to differences in the lung cancer profiles between East Asia and our Western counterparts. A higher proportion of lung cancer patients are never-smokers however, it has been found that Asians have a better survival outcome and response rates to chemotherapy. Such findings have spurred NCCS to gain a better understanding of our cancer patient profile here.

The LCCS aims to study lung cancer survival trend in the last decade for patients that come through NCCS when profiling patients’ tumours. Once profiled, the changes in survival trend with changes in therapeutic options can then be correlated and later compared with the Surveillance, Epidemiology and End Results (SEER) database.

The LCCS forms a major component of the National Lung Cancer Translational and Clinical Research (TCR) Program, which is supported by the NMRC and headed by Assoc Prof Tan Eng Huat, who is the Principal Investigator of the group.

Cancer Genetics Service (CGS)
The Cancer Genetics Service (CGS) is the clinical branch of the broader Inherited Cancer and Rare Disease Translational Research Programme. It is part of the Division of Meidical Oncology and currently headed by Dr Joanne Ngeow, a senior consultant in the Division of Medical Oncology, National Cancer Centre Singapore.

The mission of Cancer Genetics Service (CGS) is to serve as an expert base in the principles and practice of genetic and genomic medicine as a single platform for research, academic clinical practice, and education for NCCS and SingHealth. This is to ensure that personalised healthcare is based on rigorously researched and validated genetic information that can be incorporated into all healthcare decisions. The CGS serves as a self-and physician-referral-based clinical centre that provides expert genetic risk assessment for a broad array of diseases, education, genetic counselling, targeted gene testing, medical management recommendations and appropriate multi-specialty referrals. It is unique because the comprehensive clinical practice of medical genetics and genomic medicine is housed under one roof in proximity to the research on which the evidence-based practice of personalised genetic healthcare is performed. This is the first time in the history of the NCCS that a full-service genetic medicine clinical service exists.

The CGS is staffed by medical oncologists with advanced specialisation in cancer genetics. They are internationally known for their specialisation in breast, endocrine-related, gastrointestinal and urological cancers, highlighted by active and on-going contributions to cancer genetics.
The CGS carries the full suite of genetic medicine services, ranging from genetics of adult-onset disorders, such as cancer predisposition syndromes, to rare metabolic disorders. Patient visits to the CGS are set to increase with greater awareness of the role genomics plays in modern day cancer care. Common conditions seen at the CGS include Hereditary Breast and Ovarian Cancer Syndrome, Lynch syndrome, Hereditary Paraganlioma and Pheochromocytoma syndrome, Li Fraumeni syndrome and other cancer predisposition syndromes.

Clinical Trials (CTE)

NCCS is at the forefront of cancer clinical research in Singapore that is aimed at developing novel and up-to-date treatments to improve the lives of patients with different cancer types, including breast, lung, nasopharyngeal, stomach, colorectal and liver cancers. We have over a decade of experience in conducting clinical trials and have completed a broad spectrum of more than a hundred clinical trials to date. Our portfolio encompasses phases I to III trials, with most studies evaluating the effectiveness of novel molecular targeted agents.

In the Division of Medical Oncology, our investigators have been actively designing the protocols for these clinical studies. They are working closely with Clinical Trials Epidemiological Sciences department (CTE), headed by Assco Prof Tan Eng Huat, in the conduct of these trials.

Experimental Cancer Therapeutics Unit (ECRxU)

The Experimental Cancer Treatment Unit (ECRxU) was set up in 2009. It is part of the Division of Medical Oncology and headed by Dr Daniel Tan, a senior consultant in the Division of Medical Oncology, National Cancer Centre Singapore.

The primary mission of ECRxU is to bring novel therapeutic options to the clinic while concomitantly advancing the understanding of cancer biology through the design of science-driven trials. Its focus is on providing a single point of engagement for the conduct of Phase 0/1/2 trials. Through this unique translational interface, ECRxU works closely with scientists in NCCS, Duke-NUS, GIS and others, in order to increase the value of Phase I trials beyond simple does-finding studies. The unit coordinates the aspects of modern drug development from target discovery and validation, xenograft drug screening, clinical pharmacology and biomarker correlative clinical trials. This includes the ability to do sequential tumour biopsies for biomarker development in certain trials. ECRxU’s core interests cover all solid tumours and lymphomas.

From conceptualisation to the execution of biomarker intense Phase I trials, ECRxU has successfully amassed more than SGD 5 million in competitive grants as well as completed more than 30 clinical trials. In 2014, 110 patients were enrolled into Phase I trials including first-in-human studies.


Selected publications from members of the Division of Medical Oncology

1. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth
Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo SX, Low DH, Koh CM, Rambow F, Fiers M, Rogiers A, Radaelli E, Al-Haddawi M, Tan SY, Hermans E, Amant F, Yan H, Lakshmanan M, Koumar RC, Lim ST, Derheimer FA, Campbell RM, Bonday Z, Tergaonkar V, Shackleton M, Blattner C, Marine JC, Guccione E. J Clin Invest. 2016 Jan 4;126(1):68-84. doi: 10.1172/JCI82534. (IF: 13.261)

2. Antibody-drug conjugates in non-Hodgkin lymphoma. Lim ST. Lancet Oncol. 2015 Jun;16(6):607-8. doi: 10.1016/S1470-2045(15)70161-0. (IF: 24.725)

3. SETD2 Histone Modifier Loss in Aggressive Gastrointestinal Stromal Tumors
Huang KK, McPherson JR, Tay ST, Das K, Tan IB, Ng CC, Chia NY, Zhang SL, Myint SS, Hu L, Rajasegaran V, Huang D, Loh JL, Gan A, Sairi AN, Sam XX, Dominguez LT, Lee M, Soo KC, Ooi LL, Ong HS, Chung A, Chow PK, Wong WK, Selvarajan S, Ong CK, Lim KH, Nandi T, Rozen S, Teh BT, Quek R, Tan P.. Gut. 2015 Sep 3.[Epub ahead of print] (IF: 14.66)

4. Tumour vascular-disrupting agents in soft-tissue sarcoma. Quek R. Lancet Oncol. 2015 May;16(5):480-1. doi: 10.1016/S1470-2045(15)70139-7. Epub 2015 Apr 8. (IF: 24.69)

5. Association of pro-inflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: A multi-centered, prospective, cohort study.
Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, Lee JA, Fan GK, Tan YP, Yong WS, Preetha M, Loo SK, Ang SF, Wong M, Chay WY, Ooi WS, Dent RA, Yap YS, Ng R, Chan A (2015)     Ann Oncol   26(7) : 1446-51 (IF: 7.04)  

6. Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer.
Ng T, Teo SM, Yeo HL, Shwe M, Gan YX, Cheung YT, Foo KM, Cham MT, Lee JA, Tan YP, Fan G, Yong WS, Preetha M, Loh WK, Koo SL, Jain A, Lee GE, Wong M, Dent R, Yap YS, Ng R, Khor CC, Ho HK, Chan A. Neuro Oncol. nov162 (IF: 6.776)

7. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK, Heng DY (2015)    Lancet Oncol   16(3) : 293-300   (IF:  24.725)

8. Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.
Gainor JF, Tan DS, De Pas T, Solomon B, Ahmad A, Lazzari C, De Marinis F, Spitaleri G, Schultz K, Friboulet L, Yeap BY, Engelman JA, Shaw AT (2015)     Clin Cancer Res   21(12) : 2745-52  (IF: 8.722)

9. Germline Heterozygous Variants in SEC23B are Associated with Cowden Syndrome and Enriched in Apparently Sporadic Thyroid Cancer
Yehia L, Niazi F, Ni Y, Ngeow J, Sankunny M, Liu ZG, Wei W, Mester JL, Keri RA, Zhang B, Eng C. Am J Hum Genet. 2015 Nov 5;97(5):661-76. (IF: 20.931)

10. Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial.
Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S. J Clin Oncol. 2015 Jan 10;33(2):172-9. (IF: 18.428)

These 10 papers are selected from the total of 61 publications generated in 2015-2016.